Cerenome, Inc. (formerly Plus Therapeutics, Inc.) is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™ (rhenium Re-186 obisbemeda), is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CNSY | CERENOME, INC. | 2026-10-28 14:59:24 | 1.74 | 0.06 | 3.88 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNSY | 0001095981 | CERENOME, INC. | US72941H8060 | — | 330827593 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 6420 LEVIT GREEN BOULEVARD | HOUSTON | TX | 77021 | UNITED STATES | US | 737.255.7194 | 6420 LEVIT GREEN BOULEVARD, HOUSTON, TX, 77021 | 6420 LEVIT GREEN BOULEVARD, HOUSTON, TX, 77021 | PLUS THERAPEUTICS, INC. | Biotechnology / Pharmaceuticals | — | — | — | https://cerenome.com// | 31,900,000 | 7,320,345 | 7,589,625 | Cerenome, Inc. (formerly Plus Therapeutics, Inc.) is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™ (rhenium Re-186 obisbemeda), is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. | 2026-10-23 05:26:07 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 31,900,000 | 23,700,000 | 289.0244 | 171,550,698 | 154,551,072 | 909.144 |
| 2024 | 8,200,000 | 2,400,000 | 41.3793 | 16,999,626 | 12,723,544 | 297.5515 |
| 2023 | 5,800,000 | -6,300,000 | -52.0661 | 4,276,082 | -30,833,803 | -87.8209 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 5,213,000 | 5,824,000 | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | 5,213,000 | 5,824,000 | 4,913,000 |
| Research And Development Expenses | 8,379,000 | 10,580,000 | 9,690,000 |
| General And Administrative Expenses | 12,132,000 | 9,939,000 | 8,544,000 |
| Operating Expenses | 20,511,000 | 20,519,000 | 18,234,000 |
| Operating Income | -15,298,000 | -14,695,000 | -13,321,000 |
| Net Income | -22,386,000 | -12,978,000 | -13,316,000 |
| Earnings Per Share Basic | -0.29 | -1.95 | -4.24 |
| Earnings Per Share Diluted | -0.29 | -2.34 | -4.24 |
| Weighted Average Shares Outstanding Basic | 77,804,612 | 6,640,251 | 3,140,925 |
| Weighted Average Shares Outstanding Diluted | 77,804,612 | 7,700,774 | 3,140,925 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 4,256,000 | 76,000 | 8,554,000 |
| Marketable Securities Current | 4,356,000 | 3,530,000 | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,734,000 | 1,082,000 | 1,280,000 |
| Total Assets Current | 15,170,000 | 5,259,000 | 9,834,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 257,000 | 448,000 | 906,000 |
| Other Assets Non Current | 123,000 | 12,000 | 32,000 |
| Total Assets Non Current | 1,155,000 | 1,374,000 | 1,554,000 |
| Total Assets | 16,325,000 | 6,633,000 | 11,388,000 |
| Accounts Payable | 3,276,000 | 9,474,000 | 4,758,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 750,000 | 3,292,000 | 3,976,000 |
| Other Liabilities Current | 159,000 | — | — |
| Total Liabilities Current | 12,314,000 | 15,551,000 | 10,727,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 15,000 | 31,000 | 2,009,000 |
| Total Liabilities | 12,329,000 | 15,582,000 | 12,736,000 |
| Common Stock | 139,000 | 6,000 | 5,000 |
| Retained Earnings | -515,865,000 | -493,479,000 | -480,501,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 3,996,000 | -8,949,000 | -1,348,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 445,000 | 723,000 | 628,000 |
| Share Based Compensation Expense | 1,540,000 | 550,000 | 569,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 763,000 | -218,000 | -2,397,000 |
| Change In Accounts Payable | -5,620,000 | 4,702,000 | -3,677,000 |
| Change In Other Liabilities | 159,000 | — | — |
| Cash From Operating Activities | -20,775,000 | -10,554,000 | -12,851,000 |
| Purchases Of Marketable Securities | 9,353,000 | 15,590,000 | — |
| Sales Of Marketable Securities | 4,768,000 | — | — |
| Acquisition Of Property Plant And Equipment | 67,000 | 146,000 | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -854,000 | -4,111,000 | -160,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 22,615,000 | 1,000 | 5,527,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 3,292,000 | 3,996,000 | 1,608,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 30,311,000 | 6,187,000 | 3,445,000 |
| Change In Cash | 8,682,000 | -8,478,000 | -9,566,000 |
| Cash At End Of Period | 4,256,000 | 76,000 | 8,554,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | 32,000 | 222,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.29 | -1.95 | -4.24 |
| Price To Earnings Ratio | -44.1638 | -14.7436 | -10.319 |
| Earnings Growth Rate | -85.1282 | -54.0094 | 450.6494 |
| Price Earnings To Growth Ratio | 0.5188 | 0.273 | -0.0229 |
| Book Value Per Share | 0.0514 | -1.3477 | -0.4292 |
| Price To Book Ratio | 249.37 | -21.3328 | -101.9461 |
| Ebitda | -21,393,000 | -12,076,000 | -12,293,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 254,000 | 265,000 | 210,000 |
| Free Cash Flow | -21,029,000 | -10,819,000 | -13,061,000 |
| Return On Equity | -5.6021 | 1.4502 | 9.8783 |
| One Year Beta | -0.0678 | 0.9069 | -0.5016 |
| Three Year Beta | 0.0521 | 0.7104 | 0.8111 |
| Five Year Beta | 0.5818 | 1.066 | 1.2111 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Guse Kyle | Director | 2026-10-01 | 921 | A | 1,843 |
| Guse Kyle | Director | 2026-10-01 | 921 | D | 1,843 |
| ANDREWS RONALD ASBURY | Director | 2026-10-01 | 921 | A | 1,843 |
| ANDREWS RONALD ASBURY | Director | 2026-10-01 | 921 | D | 1,843 |
| HEDRICK MARC H | Director, Chief Executive Officer | 2026-10-01 | 6,387 | A | 50,870 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| STATE STREET CORP | 2026-06-30 | 134,828 | 30,853 | 4.37 |
| CITADEL ADVISORS LLC | 2026-06-30 | 111,859 | 25,597 | 4.37 |
| BARCLAYS PLC | 2026-06-30 | 420 | 96 | 4.375 |
| WELLS FARGO & COMPANY/MN | 2026-06-30 | 26,901 | 6,156 | 4.3699 |
| OSAIC HOLDINGS, INC. | 2026-06-30 | 8,740 | 2,000 | 4.37 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 12,902 | 36,383.64 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Total Market Index Fund | FSKAX | 10,097 | 28,473.54 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 2,849 | 8,034.18 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2026-08-31 | Fidelity Extended Market Index Fund | FSMAX | 41,128 | 115,980.96 | 0.0003 |
| VANGUARD INDEX FUNDS | 2026-06-30 | Institutional Select Shares | VSTSX | 203,500 | 889,295 | 0.0 |